Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: Randomized phase II study.
Annals of Oncology.
Times cited: 41
The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer.
Times cited: 1